

Table 2. (Continued)   

<table><tr><td rowspan="2">Cell line</td><td colspan="10">PKC isoform</td></tr><tr><td>α</td><td>β1/βII</td><td>γ</td><td>δ</td><td>ε</td><td>η</td><td>θ</td><td>ζ</td><td>λ/t</td><td>Detection*</td><td>Reference</td></tr><tr><td>WM115 (primary)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[36]</td></tr><tr><td>WM1205Lu (metastatic)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[36]</td></tr><tr><td>SK-Mel 28 (metastatic)</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>ND</td><td>+</td><td>+</td><td>ND</td><td>W, R</td><td>[29]</td></tr><tr><td>A375 (primary)</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>ND</td><td>+</td><td>+</td><td>ND</td><td>W, R</td><td>[29]</td><td></td></tr><tr><td>Murine</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>-</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>N</td><td>[37]</td></tr><tr><td>B16-F1 (metastatic)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[38]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>ND</td><td>ND</td><td>+</td><td>ND</td><td>N</td><td>[39]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>-</td><td>-</td><td>-</td><td>-</td><td>ND</td><td>ND</td><td>+</td><td>ND</td><td>W</td><td>[30]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[40]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>-</td><td>-</td><td>-</td><td>+</td><td>+</td><td>+</td><td>ND</td><td>+</td><td>W</td><td>[41]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[42]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>+</td><td>ND</td><td>ND</td><td>W</td><td>[43]</td></tr><tr><td>B16 (metastatic)</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>-</td><td>ND</td><td>+</td><td>ND</td><td>W</td><td>[44]</td></tr><tr><td>B16-BL6 (metastatic)</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[45]</td></tr><tr><td>B16-BL6 (metastatic)</td><td>ND</td><td>ND</td><td>ND</td><td>-</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>W</td><td>[46]</td></tr></table>

\\* N: Northern blot, F: Flow cytometry, W: Western blot, R: Reverse transcription-polymerase chain reaction. \\*\\* Not determined.  

the \(\beta\) isoform in melanocytes [49], and further showed that PKC inhibitor reduces pigmentation in murine skin in vivo [50]. It is interesting to assume that the \(\beta\) isoform is indispensable for the regulation of the tyrosinase activity, but melanin is detected even in the melanoma cells lacking the PKC \(\beta\) isoform [25,27]. On the other hand, the \(\alpha\) isoform is increased in murine B16 melanoma cells treated with retinoic acid [37,39], and the induction as well as the overexpression of this  

PKC isoform enhances the melanin synthesis, suggesting the involvement of the \(\alpha\) isoform in melanogenesis [38]. The level of the \(\alpha\) isoform is also elevated in B16 cells cultured with mannosylerythritol lipid, a novel extracellular glycolipid from yeast that induces differentiation of HL- 60 promyelocytic leukemia cells [44]. The introduction of antisense oligodeoxynucleotides against the \(\alpha\) isoform prevented mannosylerythritol lipid- induced melanogenesis, and the expression of the  

Table 3. The expression of PKC isoforms in human melanoma cells in vivo   

<table><tr><td rowspan="2">Origin</td><td colspan="10">PKC isoform</td></tr><tr><td>Clinical type*</td><td>α</td><td>β1/βII</td><td>γ</td><td>δ</td><td>ε</td><td>η</td><td>θ</td><td>ζ</td><td>λ/t</td><td>Detection**</td><td>Reference</td></tr><tr><td>Primary</td><td>ALM</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>ND***</td><td>ND</td><td>+</td><td>ND</td><td>W</td><td>[25]</td></tr><tr><td>Metastatic</td><td>Unknown</td><td>+</td><td>-</td><td>-</td><td>+</td><td>+</td><td>ND</td><td>ND</td><td>+</td><td>ND</td><td>W</td><td>[25]</td></tr><tr><td>Metastatic</td><td>NS (5 cases)</td><td>ND</td><td>+</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>I</td><td>[27]</td></tr><tr><td>Metastatic</td><td>NS (5 cases)</td><td>ND</td><td>-</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>ND</td><td>I</td><td>[27]</td></tr><tr><td>Metastatic</td><td>SSM</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>W</td><td>[28]</td></tr><tr><td>Metastatic</td><td>NS (5 cases)</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>+</td><td>-</td><td>+</td><td>+</td><td>W</td><td>[28]</td></tr><tr><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td></td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;ecel&gt;</td><td></td></tr><tr><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td></td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;-</td><td>&lt;nl&gt;</td></tr><tr><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td></td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;-</td><td>&lt;nl&gt;</td></tr><tr><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td></td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;-</td><td>&lt;nl&gt;</td></tr><tr><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td></td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;</td><td>&lt;fcel&gt;-</td><td>&lt;nl&gt;</td></tr></table>

\\*ALM: acral lentiginous melanoma: SSM: superficial spreading melanoma, NS: not stated. \\*\\*W: Western blot, I: immunohistochemistry. \\*\\*\\*Not determined.